FDA Lifts Clinical Hold on Novavax’s COVID/Flu Vaccine Candidates, Clears Phase III Trial

A trial participant developed amytrophic lateral sclerosis (ALS), an event deemed unrelated to vaccination. Novavax’s shares jumped in pre-market trading on the news but settled once markets opened.